citric acid; magnesium oxide; sodium picosulfate · Ferring Pharms Inc · NDA 209589
Clenpiq
Earliest generic entry, as listed
27 Jan 2038
Blocked by patent: US 12458634.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12458634 | drug product · sets the listed date | 27 Jan 2038 |
| US 9827231 | drug product, use U-2162 | 26 Jun 2034 |
| US 10624879 | drug product | 23 Jun 2034 |
| US 11191753 | use U-3261 | 23 Jun 2034 |
| US 12576072 | drug product, use U-3261 | 23 Jun 2034 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209589 · 001 · RLD | solution, oral | 12GM/BOT;3.5GM/BOT;10MG/BOT | 27 Jan 2038 |